Login to Your Account

'Clean sheet' Ocata advancing RPE cells in SMD, AMD trials

By Nuala Moran
Staff Writer

Monday, August 10, 2015

LONDON – Ocata Therapeutics Inc. is poised to start phase II trials of its human embryonic stem cell-derived retinal pigment epithelium (RPE) cells in the treatment of macular degeneration, which the company said will be the first such ophthalmic studies to feature placebo-controlled arms.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription